Related Experiment Video
Updated: Jul 26, 2025

08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
17.0K
Two-photon fluorescence probe for quantification of cyclosporine
Zahra Golsanamlu1,2, Jafar Soleymani3, Afshin Gharekhani4
1Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, 51656-65811, Iran.
Mikrochimica Acta
|June 20, 2023
Summary
A new fluorescent sensor accurately measures cyclosporine A (CsA) in plasma. This rapid method aids therapeutic drug monitoring for better patient outcomes.
Area of Science:
- Biomedical Engineering
- Analytical Chemistry
- Materials Science
Background:
- Cyclosporine A (CsA) requires precise therapeutic drug monitoring due to its narrow therapeutic index.
- Accurate CsA quantification is crucial for optimizing treatment efficacy and minimizing toxicity.
- Existing methods for CsA detection can be time-consuming and complex.
Purpose of the Study:
- To develop a novel ratiometric fluorescent sensor for rapid and facile determination of CsA.
- To quantify CsA in human plasma samples using a two-photon fluorescence probe.
- To evaluate the sensor's performance for on-site detection applications.
Main Methods:
- Fabrication of a ratiometric fluorescent sensor using zeolitic imidazolate framework (ZIF-8) and norepinephrine-capped silver nanoparticles (AgNPs@NE).
- Utilizing the fluorescence quenching effect of CsA on the ZIF-8-AgNPs@NE probe.
- Optimizing sensor conditions and validating the method using human plasma samples.
Main Results:
- The developed probe demonstrated a linear response for CsA quantification in two ranges: 0.01–0.5 μg mL⁻¹ and 0.5–10 μg mL⁻¹.
- Achieved a low limit of detection of 0.007 μg mL⁻¹.
- Successfully applied the method to determine CsA concentrations in plasma samples from patients on oral CsA therapy.
Conclusions:
- The novel ratiometric fluorescent sensor offers a fast, facile, and sensitive platform for CsA determination.
- The developed method shows promise for on-site therapeutic drug monitoring of CsA.
- This approach can aid in optimizing CsA dosage and improving patient management.

